IPD.AX - ImpediMed Limited

ASX - ASX Delayed price. Currency in AUD

ImpediMed Limited

50 Parker Court
Unit 1
Pinkenba, QLD 4008
61 7 3860 3700

IndustryMedical Devices
Full-time employees73

Key executives

NameTitlePayExercisedYear born
Mr. Timothy CruickshankChief Financial Officer486.89kN/AN/A
Mr. Shashi TripathiCOO & Chief Customer Officer507.24kN/AN/A
Mr. Dennis SchlahtSr. VP of R&D and Technology478.63kN/AN/A
Mr. David W. Anderson B.S., B.Sc.Exec. Director39.58kN/A1954
Mr. Richard P. ValenciaMD, CEO & DirectorN/AN/A1963
Ms. Joann YaoVP of MarketingN/AN/AN/A
Dr. Thomas SchenkChief Medical OfficerN/AN/AN/A
Ms. Leanne Ralph AAICD, ACIS, BBusCompany Sec.N/AN/AN/A
Dr. Walton A. TaylorMedical DirectorN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Corporate governance

ImpediMed Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.